Huntsman Cancer Institute (HCI) has established The Society of Huntsman Translational Scholars, an initiative that recognizes excellence in the discipline of translational science. Translational researchers extend basic discoveries made in the laboratory and apply them to solve clinical problems and benefit patients through new diagnostic and therapeutic approaches.
childhood cancer News
When construction is complete in 2020, Huntsman Cancer Institute will implement the latest advance in proton therapy, called intensity-modulated proton therapy. Proton therapy is the favored approach for many tumors in and around vital structures such as the spinal cord and brain stem. It is also the preferred treatment for certain childhood cancers. We are committed to bringing cutting-edge care to our patients, and proton therapy will be the next step in that promise.
Huntsman Cancer Institute began in 1995 with an empty lot and a dream full of promise. Twenty-two years later, HCI opened a major expansion that doubled its research capacity.
“As a physician-scientist, the patients I’ve treated who haven’t made it are always in the back of my mind, moving my laboratory work forward,” says Michael Engel, MD, PhD. His research group studies the molecular details that lead to the development of childhood leukemias and then leverages that information to combat them.